Systemic and inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

Fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients at risk for heart valve regurgitation (incompetence).

Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

Erythromycin has been associated with events secondary to QT interval prolongation such as cardiac arrest and ventricular fibrillation.

Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis

Updates have been made to the magnitude of the known risk of infantile hypertrophic pyloric stenosis following exposure to erythromycin in infancy as a result of new epidemiological data.

Letters and drug alerts sent to healthcare professionals in November 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Posted on the UK MHRA website on 17 December 2020